Slingshot members are tracking this event:

Eli Lilly and Company and AstraZeneca Announce Continuation of Pivotal Clinical Trial for People with Early Alzheimer's Disease

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
LLY Community voting in process
AZN Community voting in process

Additional Information

Additional Relevant Details AMARANTH, a Phase 2/3 study of AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for early Alzheimer's disease, will continue to Phase 3 of the Phase 2/3 seamless trial.  The AMARANTH independent data monitoring committee recommended the study continue without modification after a scheduled interim safety analysis was conducted. The analysis was not designed to review efficacy.

AZD3293 has been shown in Phase 1 studies to reduce levels of amyloid beta in the cerebro-spinal fluid of people with Alzheimer's and healthy volunteers. The progression of Alzheimer's disease is characterized by the accumulation of amyloid plaque in the brain. BACE is an enzyme associated with the development of amyloid beta. Inhibiting BACE is expected to prevent the formation of amyloid plaque and eventually slow the progression of the disease.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 08, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Early Alzheimer's Disease, Azd3293, Amaranth, Oral Beta Secretase Cleaving Enzyme, Daybreak